Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment tags : Cancer save search
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | News | $8.79 -1.79% -1.82% 2.8K
|
Health Technology
| Email alert
Add to watchlist
onct-534 first cancer treatment for study
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
Published: 2024-04-16 (Crawled : 15:00) - biospace.com/
PPCB | $0.0014 -41.86% 4.4M
|
Manufacturing
|
| O: 0.0%
H: 14.29%
C: -7.14%
patent cancer biopharma for grant
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
CADL | $5.49 0.92% 0.91% 740K
|
|
| O: 25.49%
H: 23.75%
C: 13.75%
can-2409 fda drug cancer pancreatic treatment designation for therapeutics
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.32%
H: 0.04%
C: -0.56%
ARVN | $34.3 2.54% 2.48% 800K
|
Health Technology
|
| O: 8.28%
H: 0.56%
C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
INMB | $8.79 4.27% 4.1% 98K
|
Health Technology
|
| O: 0.97%
H: 3.96%
C: 0.0%
inb03 breast cancer treatment
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Published: 2024-04-08 (Crawled : 09:00) - biospace.com/
CALT | News | $18.3 -2.35% -2.4% 6.1K
|
Health Technology
|
| O: -1.06%
H: 3.5%
C: 0.51%
patent cancer treatment for application
Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements at AACR 2024 with the Potential to Transform Cancer Diagnostics and Treatments
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: -1.81%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -3.44%
H: 0.0%
C: 0.0%
biomarker cancer diagnostics potential
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.24%
H: 0.08%
C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
EXAS | $63.45 0.36% 0.36% 1.6M
|
Health Technology
|
| O: 0.01%
H: 0.24%
C: -4.41%
cancer treatment tumor sciences
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
NBTX | $5.34 -0.74% -0.75% 28K
|
Manufacturing
|
| O: 3.11%
H: 1.19%
C: -2.54%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
lung cancer treatment
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.79%
H: 1.32%
C: 1.18%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.14%
H: 0.02%
C: -1.06%
review cancer treatment advanced china
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-03-28 (Crawled : 15:00) - prnewswire.com
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.82%
H: 0.0%
C: -2.54%
keytruda license bladder cancer treatment medical application advanced
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Adults
Published: 2024-03-28 (Crawled : 11:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
keytruda lung cancer cell risk plus
Global Particle Therapy Market Analysis and Forecasts, 2023-2033 : Revolutionizing Cancer Treatment, Particle Therapy's Rise in External Beam Radiotherapy
Published: 2024-03-27 (Crawled : 23:00) - prnewswire.com
BSGM | $1.53 -6.14% -6.54% 420K
|
Health Technology
|
| O: 3.94%
H: 4.19%
C: -10.55%
cancer global therapy market
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
Published: 2024-03-26 (Crawled : 17:00) - biospace.com/
PSNL | $1.23 2.5% 2.44% 290K
|
Health Technology
|
| O: 4.17%
H: 2.0%
C: -4.67%
personal test cancer publication treatment response
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
Published: 2024-03-26 (Crawled : 12:00) - prnewswire.com
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -1.65%
H: 3.36%
C: 3.17%
japan approved cancer treatment
Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.
Published: 2024-03-25 (Crawled : 15:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.08%
H: 0.15%
C: -0.44%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.06%
H: 0.96%
C: 0.26%
CAH | $106.0 -0.49% -0.94% 1.5M
|
Distribution Services
|
| O: 0.02%
H: 0.73%
C: -0.02%
LNTH | News | $62.34 1.4% 1.38% 1.3M
|
Health Technology
|
| O: 0.1%
H: 1.98%
C: -0.08%
reach cancer treatment market
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-03-22 (Crawled : 12:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 2.26%
H: 0.0%
C: -2.65%
chmp positive cancer treatment
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
Published: 2024-03-21 (Crawled : 12:30) - globenewswire.com
LIXT | $3.33 4.68% 18K
|
Health Technology
|
| O: -2.16%
H: 2.21%
C: 2.18%
lb-100 update cancer immunotherapy
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
Published: 2024-03-19 (Crawled : 12:30) - globenewswire.com
ATOS | $1.41 4.44% 4.26% 2.3M
|
Health Technology
|
| O: 1.55%
H: 19.85%
C: 18.32%
breast update cancer treatment program therapeutics
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.